source
- Biotech firms rally to defend FDA's mifepristone approval in Louisiana lawsuitBiotech companies, executives and investors filed an amicus brief supporting the FDA in the Louisiana case that seeks to limit access to the abortion pill mifepristone. The brief is signed by 61 e…
- Agios drops next-gen sickle cell drug after Phase 2 data show no advantage over Novo’s candidateAgios Pharmaceuticals said it is halting development of its next‑generation pyruvate kinase activator, tebapivat, for sickle cell disease after a mid‑stage trial failed to demonstrate a benefit ove…